What Will JAK Inhibitor Safety Jitters Mean For Drug Sales?

FDA Delays Decisions On Pfizer, Lilly/Incyte Drugs

 
• By Alaric DeArment
  
Slow-Down Sign_147945794_1200.jpg
The FDA delayed decisions on two JAK inhibitors from Pfizer and one from Lilly, likely because of safety concerns about the class. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip